AstraZeneca AgreementAstrazeneca Agreement • November 18th, 2011 • Delaware
This Commitment Form (“Commitment Form”) is made by and between the undersigned entity, in its capacity as an Eligible Member, for the benefit of AstraZeneca LP (“AstraZeneca”), a Delaware limited partnership, as of the Effective Date (as hereinafter defined). This Commitment Form sets forth certain terms and conditions governing the Committed Pricing Options offered by AstraZeneca for Eligible Members under the current agreement between Minnesota Multistate Contracting Alliance for Pharmacy (“GPO”) and AstraZeneca (the “Agreement”) and the NEXIUM I.V. for Injection (hereinafter referred to as "NEXIUM I.V.") Product Schedule thereto (the “Product Schedule”) with respect to NEXIUM I.V. All capitalized terms not defined in this Commitment Form shall have the meaning set forth in the Product Schedule and/or the Agreement.
AstraZeneca AgreementAstrazeneca Agreement • November 17th, 2011 • Delaware
This CRESTOR Committed Pricing Commitment Form (“Commitment Form”) is made by the undersigned entity, in its capacity as an Eligible Member, for the benefit of AstraZeneca Pharmaceuticals LP (“AstraZeneca”), a Delaware limited partnership as of the Effective Date (as hereinafter defined). This Commitment Form sets forth certain terms and conditions governing the Committed Pricing Options offered by AstraZeneca for Eligible Members under the current agreement between Minnesota Multistate Contracting Alliance for Pharmacy (“GPO”) and AstraZeneca (the “Agreement) and the CRESTOR Product Schedule thereto (the “Product Schedule”) with respect to CRESTOR. All capitalized terms not defined in this Commitment Form shall have the meaning set forth in the Product Schedule and/or the Agreement.
Nexium® (esomeprazole magnesium) For Delayed-Release Oral SuspensionAstrazeneca Agreement • November 17th, 2011 • Delaware
This Commitment Form (“Commitment Form”) is made by the undersigned entity, in its capacity as an Eligible Member, for the benefit of AstraZeneca LP (“AstraZeneca”), a Delaware limited partnership, as of the Effective Date (as hereinafter defined). This Commitment Form sets forth certain terms and conditions governing the Committed Pricing Options offered by AstraZeneca for Eligible Members under the current agreement between Minnesota Multistate Contracting Alliance for Pharmacy (“GPO”) and AstraZeneca (the “Agreement”) and the NEXIUM and NEXIUM For Delayed-Release Oral Suspension Product Schedule (collectively, hereinafter referred to as “NEXIUM”) thereto (the “Product Schedule”) with respect to NEXIUM and NEXIUM For Delayed-Release Oral Suspension. All capitalized terms not defined in this Commitment Form shall have the meaning set forth in the Product Schedule and/or the Agreement.
AstraZeneca AgreementAstrazeneca Agreement • December 1st, 2011 • Delaware
This Commitment Form (“Commitment Form”) is made by the undersigned entity, in its capacity as an Eligible Member, for the benefit of AstraZeneca Pharmaceuticals LP (“AstraZeneca”), a Delaware limited partnership, as of the Effective Date. This Commitment Form sets forth certain terms and conditions governing the Committed Pricing Options offered by AstraZeneca for Eligible Members under the current Agreement between Minnesota Multistate Contracting Alliance for Pharmacy (“GPO”) and AstraZeneca (the “Agreement”) and the ZOLADEX Product Schedule thereto (the “Product Schedule”) with respect to ZOLADEX. All capitalized terms not defined in this Commitment Form shall have the meaning set forth in the Product Schedule and/or the Agreement.
